|
1
|
Joo YH, Cho JK, Koo BS, Kwon M, Kwon SK,
Kwon SY, Kim MS, Kim JK, Kim H, Nam I, et al: Guidelines for the
surgical management of oral cancer: Korean society of thyroid-head
and neck surgery. Clin Exp Otorhinolaryngol. 12:107–144. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chi AC, Day TA and Neville BW: Oral cavity
and oropharyngeal squamous cell carcinoma - an update. CA Cancer J
Clin. 65:401–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al EORTC 24971/TAX 323 Study Group, : Cisplatin,
fluorouracil, and docetaxel in unresectable head and neck cancer. N
Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsukuda M, Kida A, Fujii M, Kono N,
Yoshihara T, Hasegawa Y and Sugita M; Chemotherapy Study Group of
Head and Neck Cancer, : Randomized scheduling feasibility study of
S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br
J Cancer. 93:884–889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harada K, Sato M, Ueyama Y, Nagayama M,
Hamakawa H, Nagahata S, Yoshimura Y, Osaki T and Ryoke K; Oral
Cancer Study Group of Chugoku-Shikoku, : Multi-institutional phase
II trial of S-1 in patients with oral squamous cell carcinoma.
Anticancer Drugs. 19:85–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokoe H, Kasamatsu A, Ogawara K, Ishigami
T, Sato Y, Shibata M, Tanzawa H and Uzawa K: Neoadjuvant
chemotherapy with S-1 for patients with oral squamous cell
carcinoma. J Cancer Sci Ther. 2:132–135. 2010. View Article : Google Scholar
|
|
7
|
Tsukahara K, Kubota A, Hasegawa Y,
Takemura H, Terada T, Taguchi T, Nagahara K, Nakatani H, Yoshino K,
Higaki Y, et al: Randomized phase III trial of adjuvant
chemotherapy with S-1 after curative treatment in patients with
squamous-cell carcinoma of the head and neck (ACTH-HNC). PLoS One.
11:1–15. 2015.
|
|
8
|
Harada K, Ferdous T and Ueyama Y:
Therapeutic strategies with oral fluoropyrimidine anticancer agent,
S-1 against oral cancer. Jpn Dent Sci Rev. 53:61–77. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al ACTS-GC Group, : Adjuvant chemotherapy for
gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med.
357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamada Y, Takahari D, Matsumoto H, Baba H,
Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y,
et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab
versus S-1 and oxaliplatin plus bevacizumab in patients with
metastatic colorectal cancer (SOFT): An open-label,
non-inferiority, randomised phase 3 trial. Lancet Oncol.
14:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Presta LG, Chen H, O'Connor SJ, Chisholm
V, Meng YG, Krummen L, Winkler M and Ferrara N: Humanization of an
anti-vascular endothelial growth factor monoclonal antibody for the
therapy of solid tumors and other disorders. Cancer Res.
57:4593–4599. 1997.PubMed/NCBI
|
|
12
|
Yoshida H, Yoshimura H, Matsuda S, Ryoke
T, Kiyoshima T, Kobayashi M and Sano K: Effects of peritumoral
bevacizumab injection against oral squamous cell carcinoma in a
nude mouse xenograft model: A preliminary study. Oncol Lett.
15:8627–8634. 2018.PubMed/NCBI
|
|
13
|
Willett CG, Boucher Y, di Tomaso E, Duda
DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et
al: Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tong M, Lloyd B, Pei P and Mallery RS:
Human head and neck squamous cell carcinoma cells are both targets
and effectors for the angiogenic cytokine, VEGF. J Cell Biochem.
105:1202–1210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vassilakopoulou M, Psyrri A and Argiris A:
Targeting angiogenesis in head and neck cancer. Oral Oncol.
51:409–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mineta H, Miura K, Ogino T, Takebayashi S,
Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A and Wennerberg J:
Prognostic value of vascular endothelial growth factor (VEGF) in
head and neck squamous cell carcinomas. Br J Cancer. 83:775–781.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith BD, Smith GL, Carter D, Sasaki CT
and Haffty BG: Prognostic significance of vascular endothelial
growth factor protein levels in oral and oropharyngeal squamous
cell carcinoma. J Clin Oncol. 18:2046–2052. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tse GM, Chan AW, Yu KH, King AD, Wong KT,
Chen GG, Tsang RK and Chan AB: Strong immunohistochemical
expression of vascular endothelial growth factor predicts overall
survival in head and neck squamous cell carcinoma. Ann Surg Oncol.
14:3558–3565. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O-charoenrat P, Rpys-Evans P and Eccles S:
Expression of vascular endothelial growth family members in head
and neck squamous cell carcinoma correlates with lymph node
metastasis. Cancer. 92:556–568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shang ZJ, Li JR and Li ZB: Circulating
levels of vascular endothelial growth factor in patients with oral
squamous cell carcinoma. Int J Oral Maxillofac Surg. 31:495–498.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng SJ, Lee JJ, Kok SH, Chou CH, Chang
HH, Yang H, Chiang ML and Kuo MY: Expression of vascular
endothelial growth factor is significantly associated with
progression and prognosis of oral squamous cell carcinomas in
Taiwan. J Formos Med Assoc. 110:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seiwert TY, Haraf DJ, Cohen EE, Stenson K,
Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX and
Vokes EE: Phase I study of bevacizumab added to fluorouracil- and
hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis
head and neck cancer. J Clin Oncol. 26:1732–1741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao M, Galanopoulos N, Lavertu P, Fu P,
Gibson M, Argiris A, Rezaee R, Zender C, Wasman J, Machtay M, et
al: Phase II study of bevacizumab in combination with docetaxel and
radiation in locally advanced squamous cell carcinoma of the head
and neck. Head Neck. 37:1665–1671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE,
Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of
four cisplatin-containing doublet combinations in stage IVB,
recurrent, or persistent cervical carcinoma: A Gynecologic Oncology
Group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wright JD, Viviano D, Powell MA, Gibb RK,
Mutch DG, Grigsby PW and Rader JS: Bevacizumab combination therapy
in heavily pretreated, recurrent cervical cancer. Gynecol Oncol.
103:489–493. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Monk BJ, Sill MW, Burger RA, Gray HJ,
Buekers TE and Roman LD: Phase II trial of bevacizumab in the
treatment of persistent or recurrent squamous cell carcinoma of the
cervix: A gynecologic oncology group study. J Clin Oncol.
27:1069–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki S, Shimazaki J, Morishita K, Koike
N, Harada N, Hayashi T and Suzuki M: Efficacy and safety of
oxaliplatin, bevacizumab and oral S-1 for advanced recurrent
colorectal cancer. Mol Clin Oncol. 5:391–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang J, Wang H and Xu Q: Bevacizumab
combined with low-dose S-1 as maintenance therapy with a long
progression-free survival in an elderly patient with heavily
pre-treated advanced gastric cancer: A case report. Biomed Rep.
1:239–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamada K, Ichiki M, Takahashi K, Hisamatsu
Y, Takeoka H, Azuma K, Shukuya T, Nishikawa K, Tokito T, Ishii H,
et al: A multicenter phase II trial of S-1 combined with
bevacizumab after platinum-based chemotherapy in patients with
advanced non-squamous non-small cell lung cancer. Cancer Chemother
Pharmacol. 78:501–507. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nie K, Geng C, Zhang L, Liu S, Zhang Z,
Wang R, Zou X and Ji Y: Clinical observation of bevacizumab
combined with S-1 in the treatment of pretreated advanced
esophageal carcinoma. Chin Med Sci J. 31:221–227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshida M, Takagane A, Miyake Y, Shimada
K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, et
al: A phase II study of third-line combination chemotherapy with
bevacizumab plus S-1 for metastatic colorectal cancer with mutated
KRAS (SAVIOR Study). Oncology. 91:24–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Harada K, Baillie R, Lu S, Syrjänen S and
Schor AM: VEGF expression in skin warts. Relevance to angiogenesis
and vasodilation. Arch Dermatol Res. 293:233–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fujita K, Sano D, Kimura M, Yamashita Y,
Kawakami M, Ishiguro Y, Nishimura G, Matsuda H and Tsukuda M:
Anti-tumor effects of bevacizumab in combination with paclitaxel on
head and neck squamous cell carcinoma. Oncol Rep. 18:47–51.
2007.PubMed/NCBI
|
|
37
|
Roland NJ, Caslin AW, Bowie GL and Jones
AS: Has the cellular proliferation marker Ki67 any clinical
relevance in squamous cell carcinoma of the head and neck? Clin
Otolaryngol Allied Sci. 19:13–18. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Itashiki Y, Harada K, Ferdous T and
Yoshida H: Effects of tumor necrosis factor-related
apoptosis-inducing ligand alone and in combination with
fluoropyrimidine anticancer agent, S-1, on tumor growth of human
oral squamous cell carcinoma xenografts in nude mice. Anticancer
Res. 27:2365–2375. 2007.PubMed/NCBI
|
|
39
|
Harada K, Supriatno, Kawashima Y, Yoshida
H and Sato M: S-1 inhibits tumorigenicity and angiogenesis of human
oral squamous cell carcinoma cells by suppressing expression of
phoshorylated Akt, vascular endothelial growth factor and
fibroblast growth factor-2. Int J Oncol. 30:365–374.
2007.PubMed/NCBI
|
|
40
|
Shirasaka T, Nakano K, Takechi T, Satake
H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, et al:
Antitumor activity of 1 M tegafur-0.4 M
5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against
human colon carcinoma orthotopically implanted into nude rats.
Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
|
|
41
|
Yoshida M, Muro K, Tsuji A, Hamamoto Y,
Yoshino T, Yoshida K, Shirao K, Miyata Y, Takahari D, Takahash T,
et al: Combination chemotherapy with bevacizumab and S-1 for
elderly patients with metastatic colorectal cancer (BASIC trial).
Eur J Cancer. 51:935–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao S, Durrani FA, Toth K, Rustum YM and
Seshadri M: Bevacizumab enhances the therapeutic efficacy of
Irinotecan against human head and neck squamous cell carcinoma
xenografts. Oral Oncol. 47:459–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X,
Zhang X, Fu J, Zhang C, Wang C, et al: Investigation of the
efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating
head and neck squamous cell carcinoma in mice. Target Oncol.
5:237–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gyanchandani R, Sano D, Ortega Alves MV,
Klein JD, Knapick BA, Oh S, Myers JN and Kim S: Interleukin-8 as a
modulator of response to bevacizumab in preclinical models of head
and neck squamous cell carcinoma. Oral Oncol. 49:761–770. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ferdous T, Harada K, Kin T, Harada T and
Ueyama Y: Efficacy of schedule-dependent metronomic S-1
chemotherapy in human oral squamous cell carcinoma cells. Int J
Oncol. 43:271–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
CELL BANK Website: HSC-2 cell, .
https://cellbank.brc.riken.jp/cell_bank/CellInfo/?cellNo=RCB1945
|
|
47
|
Takahashi K, Kanazawa H, Akiyama Y, Tazaki
S, Takahara M, Muto T, Tanazawa H and Sato K: Establishment and
characterization of a cell line (SAS) from poorly differentiated
human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc.
38:20–28. 1989.(In Japanese).
|
|
48
|
Heydar H, Mansouri K, Norooznezhad M,
Norooznezhad F, Mohamadnia A and Bahrami N: Bevacizumab inhibits
angiogenic cytokines in head and neck squamous cell carcinoma: From
gene to the protein. Int J Hematol Oncol Stem Cell Res. 12:136–141.
2018.PubMed/NCBI
|
|
49
|
Wary KK: Molecular targets for
anti-angiogenic therapy. Curr Opin Mol Ther. 6:54–70.
2004.PubMed/NCBI
|
|
50
|
Gimbrone MA Jr, Leapman SB, Cotran RS and
Folkman J: Tumor dormancy in vivo by prevention of
neovascularization. J Exp Med. 136:261–276. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Holmgren L, O'Reily MS and Folkman J:
Dormancy of micrometastasis, balanced proliferation and apoptosis
in the presence of angiogenesis suppression. Nat Med. 1:149–153.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
O'Reilly MS, Holmgren L, Chen C and
Folkman J: Angiostatin induces and sustains dormancy of human
primary tumors in mice. Nat Med. 2:689–692. 1996. View Article : Google Scholar
|
|
53
|
Folkman J and Hochberg M: Self-regulation
of growth in three dimensions. J Exp Med. 138:745–753. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Turley RS, Fontanella AN, Padussis JC,
Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine
CK, Dewhirst MW and Tyler DS: Bevacizumab-induced alterations in
vascular permeability and drug delivery: A novel approach to
augment regional chemotherapy for in-transit melanoma. Clin Cancer
Res. 18:3328–3339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Iwasaki J and Nihira S: Anti-angiogenic
therapy against gastrointestinal tract cancers. Jpn J Clin Oncol.
39:543–551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Falcetta F, Bizzaro F, D'Agostini E, Bani
MR, Giavazzi R and Ubezio P: Modeling cytostatic and cytotoxic
responses to new treatment regimens for ovarian cancer. Cancer Res.
77:6759–6769. 2017. View Article : Google Scholar : PubMed/NCBI
|
